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OBJECTIVE — Impairedglucosetolerance(IGT)representsapre-diabeticstate.Controversy
continues in regards to its pathophysiology. The aim of this study was to investigate the differ-
encesininsulinsensitivity(IS)andsecretioninobeseadolescentswithIGTcomparedwiththose
with normal glucose tolerance (NGT) and type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Atotalof12obeseadolescentswithNGT,19
with IGT, and 17 with type 2 diabetes underwent evaluation of insulin sensitivity (3-h hyper-
insulinemic [80mu/m
2/min]–euglycemic clamp), ﬁrst-phase insulin and second-phase insulin
secretion (2-h hyperglycemic clamp), body composition, and abdominal adiposity. Glucose
dispositionindex(GDI)wascalculatedastheproductofﬁrst-phaseinsulininsulinsensitivity.
RESULTS — Insulin-stimulatedglucosedisposalwassigniﬁcantlylowerinsubjectswithtype
2diabetescomparedwithsubjectswithNGTandIGT,withnodifferencebetweenthelattertwo.
However, compared with youth with NGT, youth with IGT have signiﬁcantly lower ﬁrst-phase
insulin and C-peptide levels and GDI (P  0.012), whereas youth with type 2 diabetes have an
additional defect in second-phase insulin. Fasting and 2-h glucose correlated with GDI (r 
0.68, P  0.001 and r  0.73, P  0.001, respectively) and ﬁrst-phase insulin but not
with insulin sensitivity.
CONCLUSIONS — Compared with youth with NGT, obese adolescents with IGT have
evidence of a -cell defect manifested in impaired ﬁrst-phase insulin secretion, with a more
profound defect in type 2 diabetes involving both ﬁrst- and second-phase insulin. GDI shows a
signiﬁcantly declining pattern: it is highest in NGT, intermediate in IGT, and lowest in type 2
diabetes. Such data suggest that measures to prevent progression or conversion from pre-
diabetes to type 2 diabetes should target improvement in -cell function.
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I
mpaired glucose tolerance (IGT) is a
condition of altered glucose homeosta-
sis associated with a high risk of pro-
gression to type 2 diabetes in adults (1)
andchildren(2).TheprevalenceofIGTin
children varies depending on the popula-
tion studied, with rates varying from 4.1–
4.5% in children recruited from the
community (3,4) to up to 25% in youth
from an obesity clinic (5). Also, 28% of
high-risk Latino children with positive
family history of type 2 diabetes have IGT
(6). Therefore, against the backdrop of
the obesity epidemic, IGT constitutes a
signiﬁcant problem in youth, especially
those from ethnic minority populations
and those with a family history of type 2
diabetes. However, the pathophysiology
of IGT in children is not well understood.
Inlongitudinalstudiesofadultpopula-
tionsathighriskfortype2diabetes,suchas
the Pima Indians (7), the progression from
normalglucosetolerance(NGT)toIGTand
type 2 diabetes was associated with an in-
crease in body weight, worsening of insulin
sensitivity, and decrease in biphasic insulin
secretion(7,8).Longitudinalstudiesarenot
availableinthepediatricage-group.Studies
in pediatrics using different methodologies
have shown conﬂicting results. Obese chil-
dren and adolescents with IGT were re-
portedtohavehigherBMIandworsefasting
indexesofinsulinresistancecomparedwith
those with NGT, but insulin secretion was
estimated to be similar between the two
groups (5). In overweight Latino children
with a family history of type 2 diabetes, in-
sulin sensitivity and acute insulin response
were not different but glucose disposition
index was lower in those with IGT (6). In
ourpreviousstudyofobeseadolescentgirls
with polycystic ovary syndrome (PCOS),
subjectswithIGTandsubjectswithNGTof
similar body composition and abdominal
fat distribution had similar insulin sensitiv-
ity but lower ﬁrst-phase insulin secretion
and lower glucose disposition index (9). In
the present study, we aimed to extend our
previous observation and to investigate the
differences in insulin sensitivity and insulin
secretion not only between subjects with
NGT and subjects with IGT but also be-
tweenthosewithIGTandthosewithtype2
diabetes. We hypothesized that 1) insulin
sensitivity is not signiﬁcantly different be-
tween equally obese youth with IGT and
those with NGT and 2) insulin secretion is
impaired in IGT and type 2 diabetes com-
pared with NGT, with a severity gradient
from IGT to type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Study population
Atotalof12obeseadolescentswithNGT,
19 with IGT, and 17 with type 2 diabetes
were studied; subjects were African-
American and American Caucasian. All
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notinvolvedinanyregularphysicalactiv-
ity or weight-reduction programs. They
were recruited through ﬂyers posted in
thecommunityandthehealthcenter.The
NGT and IGT adolescents had normal
fasting glucose (100 mg/dl), with a 2-h
glucose value during an oral glucose tol-
erance test (OGTT) of 140 mg/dl in
NGTand140–199mg/dlinIGTsubjects.
They were not on any medications that
affect glucose metabolism. The adoles-
cents with type 2 diabetes were clinically
diagnosed according to American Diabe-
tes Association and World Health Orga-
nization criteria (10), with a mean A1C of
10.13.0%andglucoselevelof277.2
158.2 mg/dl at presentation and negative
glutamic acid decarboxylase and islet cell
autoantibodies. They all had adequate
metaboliccontrol,withanaverageA1Cof
6.6  0.2% (range 4.7–8.3%) and aver-
age duration of diabetes of 4.8  5.7
months (0–18 months). They were on
treatment consisting of lifestyle changes
alone (n  3), metformin (n  6), met-
formininsulin(n7),orinsulinalone
(n  1). Metformin and long-acting insu-
lin were discontinued 48 h before the
clamp studies. All studies were approved
by the institutional review board of the
University of Pittsburgh. Informed con-
sent was obtained. Characteristics of the
study participants are summarized in Ta-
ble 1.
Clamp studies
Participants were admitted twice within a
1–3 week period to the Pediatric Clinical
and Translational Research Center on the
days before the clamp studies, and a
hyperinsulinemic-euglycemic clamp and
a hyperglycemic clamp study were per-
formedinrandomorder.Eachparticipant
underwent a 2-h OGTT (1.75 g/kg of glu-
cola [max 75 g]) the day before the ﬁrst
clamp.
In vivo insulin sensitivity
A fasting blood sample was obtained for
determination of total cholesterol, LDL
cholesterol, HDL cholesterol, VLDL cho-
lesterol, triglycerides, and A1C. Fasting
endogenous glucose production was
measured with a primed constant rate in-
fusion of [6, 6-
2H2] glucose (0.306 
0.009 mol   kg
1   min
1) (Isotech, Mi-
amisburg, OH) (11,12). Blood was sam-
pled at the start of the 2-h stable isotope
infusion and every 10 min from 30 to 0
min (basal period) for determination of
plasma glucose, insulin, and isotopic en-
richment of glucose. Following this basal
period, insulin-mediated glucose metab-
olism and substrate utilization were eval-
uated during a 3-h hyperinsulinemic-
euglycemic clamp (11,12). Intravenous
crystalline insulin (Humulin; Lilly India-
napolis, IN) was infused at a constant rate
of80mU/m
2permin,andplasmaglucose
wasclampedat5.6mmol/lwithavariable
rate infusion of 20% dextrose as before
(11). Continuous indirect calorimetry
(Deltatrac Metabolic Monitor; Sensor-
medics, Anaheim, CA) was used to mea-
sure CO2 production, O2 consumption,
and respiratory quotient for 30 min at
baseline and at the end of the euglycemic
clamp (12).
In vivo insulin secretion
First and second-phase insulin secretion
was evaluated during a 2-h hyperglyce-
mic clamp (12.5 mmol/l) as previously
described (11).
Body composition
Body composition was determined by a
dual-energy X-ray absorptiometry scan.
Subcutaneous abdominal adipose tissue
and visceral adipose tissue (VAT) were
determinedbyasingle-slicecomputedto-
mography (CT) scan at L4-L5, as before
(11).
Biochemical measurements
Plasma glucose was measured with a glu-
cose analyzer (Yellow Springs Instru-
ment, Yellow Springs, OH), and insulin,
C-peptide, and adiponectin were mea-
sured by radioimmunoassay, as before
(11). A1C was measured by high-
performance liquid chromatography
(Tosoh Medics), and lipids were mea-
Table1—PhysicalcharacteristicsandfastingmetabolicproﬁleinadolescentswithNGT,IGT,
and type 2 diabetes
NGT IGT Type 2 diabetes
n 12 19 17
Age (years) 14.2  2.2 13.8  1.5 14.7  1.3
Sex (male/female)* 4/8 6/13 7/10
Ethnicity*
African American 5 5 7
American Caucasian 7 14 10
Tanner Stage*
II–III 4 3 2
IV–V 8 16 15
Estradiol in females (pmol/l) 232.7  171.1 294.8  211.8 222.8  161.9
DHEAS (nmol/l)
Females 3,669.28  759.2 4,108.8  3,001.4 3,687.0  1,902.0
Males 3,659.9  1,366.0 5,415.0  3,085.7 4,139.9  2,332.0
BMI (kg/m
2) 36.0  5.2 35.0  6.6 36.3  5.3
Waist circumference (cm) 108.5  18.9 104.3  14.2 107.9  11.8
% Body fat 45.4  4.7 44.3  4.3 41.0  6.8
Fat mass (kg) 40.0  6.9 40.7  10.9 40.1  10.5
Subcutaneous abdominal fat
(cm
2) 545.7  168.6 501.6  145.7 520.1  152.4
Visceral fat (cm
2) 75.8  48.3 72.1  25.1 78.7  25.2
A1C (%) 5.2  0.5
a 5.3  0.4
b 6.8  0.8
Fasting glucose (mmol/l) 5.1  0.02
a 5.1  0.2
b 6.6  1.4
Fasting insulin (pmol/l) 252.6  95.1 240.0  130.7 274.2  142.0
Hepatic glucose production
(mol   kg
1   min
1) 10.5  1.9 12.8  3.5 13.3  2.3
Cholesterol (mmol/l) 4.6  0.9 4.3  0.8 3.9  0.8
HDL cholesterol (mmol/l) 1.1  0.3 1.0  0.3 0.9  0.2
LDL cholesterol (mmol/l) 2.9  0.9 2.6  0.7 2.3  0.6
Triglycerides (mmol/l) 1.5  0.6 1.8  1.0 1.4  0.8
Data are means  SD unless otherwise indicated. Four IGT subjects had VAT and subcutaneous abdominal
adipose tissue evaluation by abdominal magnetic resonance imaging. Excluding these subjects from the
analysisdoesnotchangethedata.SuperscriptsareANOVAPvaluesforpost-hocanalysis:a,P0.05inNGT
vs.type2diabetes;b,P0.05inIGTvs.type2diabetes.*The	
2analysisrevealednosigniﬁcantdifferences
among groups with respect to ethnicity, sex, and Tanner stage. DHEAS, dehydroepiandrosterone sulfate.
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for Disease Control and Prevention (11).
Deuterium enrichment of glucose in the
plasma was determined on a Hewlett-
Packard Co. 5973 mass spectrometer
(Palo Alto, CA) coupled to a 6,890 gas
chromatograph (11,12).
Calculations
Fasting hepatic glucose production
(HGP) was calculated during the last 30
min of the 2-h isotope infusion according
to steady-state tracer dilution equations
(11). Insulin-stimulated glucose disposal
rate(Rd)wascalculatedduringthelast30
min of the euglycemic clamp to be equal
to the rate of exogenous glucose infusion.
Peripheral insulin sensitivity was calcu-
lated by dividing the Rd by the steady-
state clamp insulin level (11). Insulin-
stimulated carbohydrate oxidation rates
werecalculatedaccordingtotheformulas
of Frayn (12) from the indirect calorime-
try data. Nonoxidative glucose disposal
was estimated by subtracting the rate of
glucose oxidation from the total Rd. Dur-
ing the hyperglycemic clamp, the ﬁrst-
and second-phase insulin and C-peptide
concentrations were calculated as de-
scribed previously (11,12). Glucose dis-
positionindex(GDI)wascalculatedasthe
product of insulin sensitivity  ﬁrst-
phase insulin.
Statistics
Statistical analyses were performed using
three-way ANOVA followed by post hoc
Bonferroni or Dunnett’s correction.
Kruskal-Wallis test was used for multiple
group comparison of nonparametric vari-
ables. Spearman’s correlation and multi-
ple regression analyses were used to
evaluate bivariate and multivariate rela-
tionships, respectively, and 	
2 was used
to evaluate nonparametric variables. Data
are presented as means  SD. Two-tailed
P  0.05 was considered statistically
signiﬁcant.
RESULTS
Study subjects
Table 1 depicts the physical characteris-
tics and fasting metabolic proﬁle of the
participants (NGT vs. IGT vs. type 2 dia-
betes). There were no signiﬁcant differ-
ences in age, pubertal stage, or ethnic
distribution among the three groups.
There were no signiﬁcant differences in
bodycompositionorabdominalfatdistri-
bution among the three groups.
Fasting metabolic proﬁle
There were no signiﬁcant differences in
fastinglipidsandinsulinlevelsamongthe
three groups. Fasting glucose and A1C
were signiﬁcantly higher in type 2 dia-
betic subjects compared with the two
other groups. HGP was 20% higher in
subjects with type 2 diabetes compared
with the NGT group (P  0.078). A1C
did not differ among the four groups of
type 2 diabetic subjects on different treat-
ments (A1C 6.5  0.5% with lifestyle
alone, 7.0  0.7% with metformin alone,
6.7  1.1% with metformin  insulin,
and 6.9% with insulin alone).
Clamp data
During the hyperinsulinemic-euglycemic
clamp, steady-state glucose and insulin
levels were not different among the three
groups (NGT, IGT, type 2 diabetes) (glu-
cose: 5.6  0.08, 5.6  0.10, and 5.6 
0.13 mmol/l, respectively; insulin:
2,020.8  587.2, 1,737.6  508.9, and
1,791.6  674.2 pmol/l, respectively).
Insulin-stimulated total and oxidative
glucose disposal were not different be-
tween NGT and IGT but were signiﬁ-
cantly lower in type 2 diabetes (Fig. 1-A).
Nonoxidative glucose disposal tended to
be lower in those with type 2 diabetes
than in those with NGT and IGT (P 
0.08) (Fig. 1-A). The data remained con-
sistent when Rd was expressed per kg of
fat-free mass (mol   min
1   kg
1)( P 
0.006).
During the hyperglycemic clamp, the
IGT adolescents had lower ﬁrst-phase in-
sulin and C-peptide levels than subjects
with NGT, with no difference in second-
phase insulin (Table 2, Fig. 1B). Type 2
diabetic adolescents had lower ﬁrst- and
second-phase insulin and C-peptide lev-
els compared with adolescents with NGT
and a tendency for lower second-phase
insulin (P  0.07) and lower second-
phase C-peptide (P  0.012) compared
with adolescents with IGT (Table 2, Fig.
1-B). GDI was signiﬁcantly lower in IGT
compared with NGT and lowest in type 2
diabetes (Fig. 1-C). GDI did not differ in
the type 2 diabetic subjects in the four
treatment groups (0.5  0.3 mmol   kg
1
  min
1 in the lifestyle, 0.6  0.4 mmol
  kg
1   min
1 in the metformin alone,
0.6  0.3 mmol   kg
1   min
1 in the
metformin  insulin, and 0.6 mmol  
kg
1 min
1intheinsulinalonegroups).
Relationship between OGTT indexes
of glucose tolerance and clamp data
The 2-h glucose level during the OGTT
correlated with GDI (r  0.73, P 
0.001) and ﬁrst-phase (r  0.69, P 
0.001) and second-phase (r  0.59,
P0.001)insulin,butitdidnotcorrelate
with insulin sensitivity (r  0.13, P 
0.4) (Fig. 2). In multiple regression anal-
ysis with 2-h glucose post-OGTT as the
dependent variable and VAT, GDI, and
second-phase insulin as the independent
variables, GDI ( 0.54, P  0.001)
but not second-phase insulin nor VAT
contributed signiﬁcantly to the variance
inthe-2hglucose(R
20.44,P0.001).
Similarly, fasting glucose correlated with
GDI (r  0.68, P  0.001) and ﬁrst-
phase (r  0.61, P  0.001) and sec-
ond-phase (r  0.53, P  0.001)
insulin levels but not with insulin sensi-
tivity (r  0.2, P  0.3).
CONCLUSIONS — The present in-
vestigation demonstrates that IGT in
youth is characterized by impaired insu-
lin secretion relative to insulin sensitivity.
The GDI is lowest in youth with type 2
diabetes, intermediate in those with IGT,
and highest in those with NGT. Com-
pared with NGT, glucose disposition in-
dex is 
40% lower in those with pre-
diabetes and 80% lower in those with
type 2 diabetes. While insulin secretion is
impaired in IGT, insulin-stimulated glu-
cose disposal is not different from that in
NGT. In youth with type 2 diabetes, the
impairmentin-cellfunctionisofgreater
magnitudeandinvolvessecond-phasein-
sulin secretion as well. The current study
adds to the limited existing literature by
1) providing a comparison between three
groups of equally obese adolescents
(those with NGT, IGT, and type 2 diabe-
tes) of similar BMI, pubertal stage, body
composition, and abdominal fat distribu-
tion and 2) providing information on in
vivoinsulinsensitivityandsecretionmea-
sured simultaneously by the clamp meth-
odology.
Impaired glucose tolerance is a well-
known pre-diabetic state with a linear re-
lationship between the 2-h postchallenge
glucose levels and subsequent risk for
type 2 diabetes in adult prospective stud-
ies (1), with observed rates of progression
from IGT to type 2 diabetes from 20%
(13) to 60% (14,15) over an average du-
ration of 2–8 years (1). Impaired glucose
tolerance seems amenable to intervention
with prevention of type 2 diabetes re-
Metabolic differences in IGT, NGT, and type 2 diabetes
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withlifestyleinterventionbeingatleastas
effective if not more effective than phar-
macotherapy (16). Therefore, it is impor-
tant to identify and characterize the
pathopysiologicalmechanism(s)underly-
ing IGT in youth in an effort to provide
targeted intervention and prevention of
progression to type 2 diabetes.
Our current ﬁndings are consistent
with data in adults with IGT, where lon-
gitudinal studies point to the deteriora-
tion in insulin secretion relative to insulin
sensitivity in the transition from NGT to
IGT to type 2 diabetes (8). Pima Indians
with isolated IGT had a modest decrease
in acute insulin response (AIR), as mea-
suredbyanintravenousglucosetolerance
test, which was signiﬁcant given in-
creased insulin resistance in subjects with
IGTcomparedwiththosewithNGT(17).
However, in these adult studies, the de-
crease in insulin sensitivity in subjects
with IGT was attributed to aging over the
5yearsofthestudy(8)ortohigherBMIin
the subjects with IGT (17). In our study,
NGT and IGT groups had comparable
obesity and body fat distribution. Fur-
thermore, in Pima Indians, a greater de-
fect in AIR was found in those who
subsequently developed type 2 diabetes
(7). Similarly, in Mexican Americans, the
7-year risk of progression to type 2 diabe-
tes was signiﬁcantly higher in subjects
with IGT than in those with NGT (OR 
9.4),andbothdecreasedinsulinsecretion
(determined by  I30/ G30) and insulin
resistance independently predicted the
progression to type 2 diabetes (18).
These adult longitudinal studies sup-
porttheroleofimpaired-cellfunction
in the risk of progression from NGT to
IGT to type 2 diabetes. Studies in pedi-
atrics examining IGT have been few and
somewhat contradictory.
Table 2—Hyperglycemic clamp data in the three groups
NGT IGT
Type 2
diabetes ANOVA
n 12 19 17 P
First-phase insulin
(pmol/l) 2,376.0  1,729.9
a,b 1,182.0  625.2 708.0  938.4 0.001
First-phase C-peptide
(nmol/l) 4.3  2.0
b 3.0  1.0 2.2  1.4 0.001
Second-phase insulin
(pmol/l) 2,563.2  1,363.2
b 1,902.6  1,336.2 982.2  797.0 0.003
Second-phase C-
peptide (nmol/l) 5.0  1.5
b 4.7  1.9
c 3.0  1.1 0.002
Data are means  SD unless otherwise indicated. C-peptide levels were not available in 3 subjects with IGT.
Superscripts are ANOVA P values for post-hoc analysis (Bonferroni correction): a, P  0.05 in NGT vs. IGT;
b, P  0.05 in NGT vs. type 2 diabetes; c: P  0.05 in IGT vs. type 2 diabetes.
Figure 1—A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in NGT ( ), IGT (z), and type 2 diabetes (f). B: First and
second-phaseinsulinlevelsinNGT(‚),IGT(z),andtype2diabetes(F).C:GlucosedispositionindexinNGT,IGT,andtype2diabetes.Errorbars
reﬂect SEs.
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sured by the hyperinsulinemic-
euglycemic clamp method, was reported
in adolescents with IGT compared with
control subjects with NGT, with no sig-
niﬁcant differences in insulin secretion
(19). However, the group with IGT had a
signiﬁcantly higher ratio of visceral to
subcutaneous abdominal fat (P  0.002).
We previously demonstrated that higher
visceral fat is associated with lower insu-
lin sensitivity in obese insulin-resistant
youth (12). Thus, the lower insulin sensi-
tivity in IGT in the former study could be
relatedtothehigherlevelofvisceralfat.In
another study, the same group reported
that IGT is characterized by a decline in
AIR, based on OGTT data (20). In that
study,thechildrenwithIGTwereheavier
and had signiﬁcantly higher BMI z scores
than children with NGT, but abdominal
adiposity was not evaluated (20). How-
ever, when researchers evaluated subjects
withNGT,IGT,andofsimilarBMIand%
body fat using mathematical modeling of
the hyperglycemic clamp data, the glu-
cose sensitivity of ﬁrst-phase insulin se-
cretion declined from NGT to IGT and
from IGT to type 2 diabetes (although ab-
solute insulin levels did not) (21). Also,
recently, they reported decreased glucose
sensitivity of ﬁrst-phase insulin secretion
insubjectswithIGTcomparedwiththose
with NGT, which was consistent with our
ﬁndings (22). The different ﬁndings in
thesestudiescouldbeattributedtodiffer-
ent methodologies used and the differ-
ences in BMI and body composition
between the NGT and IGT groups. Data
in high-risk overweight Latino children
were consistent with our present observa-
tions.SubjectswithNGTandIGTofsimilar
bodycompositionandabdominalfatdistri-
bution had similar insulin sensitivity, but
subjects with IGT had relative insulin deﬁ-
ciency with signiﬁcantly lower GDI than
those with NGT (6). Lastly, the current
ﬁndings conﬁrm our previous observa-
tions in girls with PCOS (9).
With regards to type 2 diabetes, the
impairment in ﬁrst-phase insulin secre-
tion is of greater magnitude than that in
IGT, with the added dysfunction in sec-
ond-phase insulin. In type 2 diabetes,
ﬁrst-phase insulin is 
70% lower than
thatinNGTand
40%lowerthanthatin
IGT. Second-phase insulin is 
60%
lower in type 2 diabetes than in NGT, but
it is preserved in IGT. This is consistent
withourpreviousreportofdecreasedsec-
ond-phaseinsulinlevelsintype2diabetic
subjects vs. obese control subjects (23)
and with the ﬁndings of Weiss et al. (20)
ofdecreasedglucosesensitivityofsecond-
phase insulin in type 2 diabetic subjects.
Hepatic glucose production was
higher in type 2 diabetes than in NGT.
This is consistent with our previous re-
port of increased HGP in type 2 diabetic
youth than in obese control subjects (23)
and with adult data suggesting that in-
creased endogenous glucose production
contributestofastinghyperglycemia(17).
Finally, our data demonstrate that ﬁrst-
phase insulin and GDI are signiﬁcant de-
terminants of measures of glycemic
regulation, including fasting glucose and
2-hglucoseduringtheOGTT.Theseﬁnd-
ings are in agreement with our ﬁndings in
girls with PCOS (9) and with the adult
literature in terms of the determinants of
the glycemic status in subjects with IGT,
although all the variables were not mea-
sured simultaneously in these subjects
(24,25).
A potential limitation of the current
study is that the IGT subjects were com-
pared with type 2 diabetic children with
different treatment modalities and diabe-
tes duration. However, data analysis per-
formed separately in the type 2 diabetic
subjects did not show any signiﬁcant dif-
ferences in A1C or GDI in the four treat-
ment groups. Also, the majority of these
adolescents (12 out of 17) were studied
within 6 months of diagnosis of type 2
diabetes, with no signiﬁcant difference in
GDI or A1C when evaluated according to
duration of diabetes and no relationship
between duration of diabetes and A1C,
which was consistent with our previous
ﬁndings (23). The other limitation of the
relativelysmallersamplesize(NGT12)
is offset by the use of the clamp method-
ology, which allowed us to demonstrate
signiﬁcant differences among the three
groups.
In summary, our ﬁndings demon-
strate that pre-diabetes, or IGT, is an
intermediate stage in the impairment of
-cell function relative to insulin resis-
tance, with type 2 diabetes having a
more pronounced defect in ﬁrst- and
second-phase insulin secretion. Such
data suggest that measures to prevent
conversion/progression of IGT to type 2
diabetesshouldtargetrecoveryof-cell
Figure 2— Relation of ﬁrst-phase insulin and GDI to the 2-h glucose during the OGTT in NGT (‚), IGT (z), and type 2 diabetes (F).
Metabolic differences in IGT, NGT, and type 2 diabetes
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obesity and insulin resistance. The
ultimate objective is restoration of glu-
cose homeostasis through improved
balance between insulin sensitivity and
secretion.
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